載入中
NASDAQHealthcareBiotechnology
最新資料
US$28.14
+US$0.94 · +3.46%
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
前收盤價
US$28.14
+US$0.94 · +3.46%
盤中時間採用ET。市場資料可能有所延遲。
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
日內區間
目前US$28.14
52週區間
目前US$28.14
盤中時間採用ET。市場資料可能有所延遲。
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
日內區間
目前US$28.14
52週區間
目前US$28.14
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | 8737.1萬 USD | 3.81億 USD | 2223萬 USD | — |
| 銷貨成本 | 52.5萬 USD | 4215.6萬 USD | 2544.1萬 USD | 299.3萬 USD | — |
| 毛利 | −52.5萬 USD | 4521.5萬 USD | 3.55億 USD | 1923.7萬 USD | — |
| 研究與開發 | 9040.4萬 USD | 1.04億 USD | 1.28億 USD | 9345萬 USD | 4404萬 USD |
| 銷售、一般及管理費用 | 6288.7萬 USD | 1.14億 USD | 1.88億 USD | 1.27億 USD | 3893.3萬 USD |
| 營業費用 | 1.53億 USD | 3.6億 USD | 3.17億 USD | 2.21億 USD | 8268.8萬 USD |
| 利息收入 | 930.2萬 USD | 1380.9萬 USD | 1615.5萬 USD | 429.1萬 USD | 3.6萬 USD |
| 折舊和攤銷 | 52.5萬 USD | 90.4萬 USD | 108.8萬 USD | 48.7萬 USD | 5.2萬 USD |
| 營業利益 | −1.53億 USD | −3.15億 USD | 3880.2萬 USD | −2.01億 USD | −8268.8萬 USD |
| 淨利 | −1.45億 USD | −3.02億 USD | 4927.1萬 USD | −1.98億 USD | −8793.1萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$52.20
上漲空間 85.50%AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
